A pooled analysis across four clinical trials evaluating delandistrogene moxeparvovec in predominantly young ambulatory patients with Duchenne muscular dystrophy found a manageable cardiac safety profile over up to five years of follow-up. The analysis focused on longer-term tolerability signals in a population where cardiac outcomes are a primary driver of morbidity. For gene-therapy developers, the report adds longer-duration real-world style safety information that can support ongoing risk-benefit discussions and monitoring parameters as these therapies move beyond early-stage evaluation.